amsacrine has been researched along with Breast Cancer in 35 studies
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of in-silico studies provide strong evidence for the potential of valuable ligands in pyrazole substituted 9-anilinoacridines as HER2 inhibitors, and the compounds, 1v,s,r,d,a,o with significant Glide scores may produce significant anti-breast cancer activity." | 8.12 | Pyrazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer - An in-silico approach. ( Byran, G; Gomathi, S; Rajagopal, K; Sri, VB, 2022) |
| "Twelve patients with recurrent and metastatic breast cancer were treated with a combination of adriamycin and amsacrine (m-AMSA) to evaluate its efficacy and toxicity." | 7.67 | Pilot study of adriamycin and amsacrine (m-AMSA) in patients with advanced breast cancer. ( Camacho, FJ; Chang, AY; Kaplan, BH; Solan, A; Taylor, SG; Vogl, SE, 1988) |
| "In 117 primary breast cancers, 25 were amplified for erbB2." | 5.29 | Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. ( Carmichael, J; Greenall, M; Harris, AL; Houlbrook, S; Smith, K, 1993) |
| "The results of in-silico studies provide strong evidence for the potential of valuable ligands in pyrazole substituted 9-anilinoacridines as HER2 inhibitors, and the compounds, 1v,s,r,d,a,o with significant Glide scores may produce significant anti-breast cancer activity." | 4.12 | Pyrazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer - An in-silico approach. ( Byran, G; Gomathi, S; Rajagopal, K; Sri, VB, 2022) |
| "The etoposide-resistant human breast cancer cell line MDA-VP was derived from MDA-parent cells by sequential selection in increasing concentrations of etoposide." | 3.69 | Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide. ( An, T; Asano, T; Fojo, AT; Kleinerman, ES; Takano, H; Zwelling, LA, 1996) |
| " Using an alkaline DNA-unwinding technique to detect drug-induced DNA strand breakage, we have shown that estrogen stimulation of T-47D human breast cancer cells enhances induction of DNA cleavage by etoposide (VP-16), 4',9-acridinylaminomethanesulfon-m-anisidide (m-AMSA), mitoxantrone, and doxorubicin, drugs known to interact with the DNA-modifying enzyme topoisomerase II." | 3.67 | Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs. ( Epstein, RJ; Smith, PJ, 1988) |
| "Twelve patients with recurrent and metastatic breast cancer were treated with a combination of adriamycin and amsacrine (m-AMSA) to evaluate its efficacy and toxicity." | 3.67 | Pilot study of adriamycin and amsacrine (m-AMSA) in patients with advanced breast cancer. ( Camacho, FJ; Chang, AY; Kaplan, BH; Solan, A; Taylor, SG; Vogl, SE, 1988) |
| "m-AMSA is a new drug in the National Cancer Institute Drug Development Program." | 2.65 | m-AMSA: an exciting new drug in the National Cancer Institute Drug Development Program. ( Charles, LM; Macdonald, JS; Weiss, RB, 1980) |
| "In 117 primary breast cancers, 25 were amplified for erbB2." | 1.29 | Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. ( Carmichael, J; Greenall, M; Harris, AL; Houlbrook, S; Smith, K, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (48.57) | 18.7374 |
| 1990's | 6 (17.14) | 18.2507 |
| 2000's | 6 (17.14) | 29.6817 |
| 2010's | 5 (14.29) | 24.3611 |
| 2020's | 1 (2.86) | 2.80 |
| Authors | Studies |
|---|---|
| Stanslas, J | 1 |
| Hagan, DJ | 1 |
| Ellis, MJ | 1 |
| Turner, C | 1 |
| Carmichael, J | 3 |
| Ward, W | 1 |
| Hammonds, TR | 1 |
| Stevens, MF | 1 |
| Islam, MS | 1 |
| Park, S | 2 |
| Song, C | 1 |
| Kadi, AA | 1 |
| Kwon, Y | 2 |
| Rahman, AF | 1 |
| Kadayat, TM | 1 |
| Shrestha, A | 1 |
| Jo, H | 1 |
| Hwang, SY | 1 |
| Katila, P | 1 |
| Shrestha, R | 1 |
| Nepal, MR | 1 |
| Noh, K | 1 |
| Kim, SK | 1 |
| Koh, WS | 1 |
| Kim, KS | 1 |
| Jeon, YH | 1 |
| Jeong, TC | 1 |
| Lee, ES | 1 |
| Kalirajan, R | 1 |
| Pandiselvi, A | 1 |
| Gowramma, B | 1 |
| Balachandran, P | 1 |
| Rajagopal, K | 1 |
| Sri, VB | 1 |
| Byran, G | 1 |
| Gomathi, S | 1 |
| Zang, X | 1 |
| Zhang, J | 1 |
| Zhou, Y | 1 |
| Chen, Q | 1 |
| Peng, Y | 1 |
| Sun, J | 1 |
| Liu, J | 1 |
| Liu, W | 1 |
| Wang, G | 1 |
| Zhou, F | 1 |
| Fang, YP | 1 |
| Wu, PC | 1 |
| Huang, YB | 1 |
| Tzeng, CC | 1 |
| Chen, YL | 1 |
| Hung, YH | 1 |
| Tsai, MJ | 1 |
| Tsai, YH | 1 |
| Bacherikov, VA | 2 |
| Chou, TC | 2 |
| Dong, HJ | 2 |
| Chen, CH | 2 |
| Lin, YW | 2 |
| Tsai, TJ | 2 |
| Su, TL | 2 |
| Zhang, X | 1 |
| Lee, RZ | 1 |
| Liu, LF | 1 |
| Tannir, N | 1 |
| Spitzer, G | 1 |
| Schell, F | 1 |
| Legha, S | 1 |
| Zander, A | 1 |
| Blumenschein, G | 1 |
| Carter, SK | 1 |
| Currie, VE | 1 |
| Howard, J | 1 |
| Wittes, R | 1 |
| De Lena, M | 1 |
| Rossi, A | 1 |
| Bonadonna, G | 1 |
| Amrein, PC | 1 |
| Coleman, M | 1 |
| Richards, F | 1 |
| Poulin, RF | 1 |
| Bernhardt, B | 1 |
| Ginsberg, SJ | 1 |
| Green, MR | 1 |
| Morrison, A | 1 |
| Cortes, E | 1 |
| Kiang, D | 1 |
| Weinberg, V | 1 |
| Wood, WC | 1 |
| Buzdar, AU | 2 |
| Legha, SS | 1 |
| Hortobagyi, GN | 2 |
| Powell, KC | 1 |
| Blumenschein, GR | 2 |
| Bodey, GP | 2 |
| Horikoshi, N | 1 |
| Ogawa, M | 1 |
| Inagaki, J | 1 |
| Ezaki, K | 1 |
| Inoue, K | 1 |
| Okabe, K | 1 |
| Nagata, T | 1 |
| Aiba, K | 1 |
| Domyo, M | 1 |
| Issell, BF | 2 |
| Weiss, RB | 1 |
| Charles, LM | 1 |
| Macdonald, JS | 1 |
| Smith, K | 1 |
| Houlbrook, S | 2 |
| Greenall, M | 1 |
| Harris, AL | 3 |
| Kirk, J | 1 |
| Stuart, NS | 1 |
| Stratford, IJ | 1 |
| Asano, T | 1 |
| An, T | 1 |
| Zwelling, LA | 2 |
| Takano, H | 4 |
| Fojo, AT | 1 |
| Kleinerman, ES | 1 |
| Tortora, G | 1 |
| Ciardiello, F | 1 |
| Damiano, V | 1 |
| Pepe, S | 1 |
| Bianco, C | 1 |
| di Isernia, G | 1 |
| Davies, SL | 1 |
| North, P | 1 |
| Hickson, ID | 1 |
| Matsumoto, Y | 3 |
| Kunishio, K | 2 |
| Nagao, S | 3 |
| Fojo, T | 3 |
| Lefevre, D | 1 |
| Riou, JF | 1 |
| Ahomadegbe, JC | 1 |
| Zhou, DY | 1 |
| Benard, J | 1 |
| Riou, G | 1 |
| Hill, BT | 1 |
| Whelan, RD | 1 |
| Hosking, LK | 1 |
| Shellard, SA | 1 |
| Hinds, MD | 1 |
| Mayes, J | 1 |
| Hanauske, AR | 2 |
| Hanauske, U | 1 |
| Von Hoff, DD | 3 |
| Epstein, RJ | 2 |
| Smith, PJ | 2 |
| Lathan, B | 1 |
| Clark, GM | 1 |
| Elslager, EE | 1 |
| Chang, AY | 1 |
| Solan, A | 1 |
| Kaplan, BH | 1 |
| Vogl, SE | 1 |
| Camacho, FJ | 1 |
| Taylor, SG | 1 |
| Casimir, MT | 1 |
| Louie, AC | 1 |
4 reviews available for amsacrine and Breast Cancer
| Article | Year |
|---|---|
New cytotoxic drugs for breast cancer and their clinical evaluation.
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as | 1980 |
The human tumor cloning assay in cancer research and therapy: a review with clinical correlations.
Topics: Aminoacridines; Amsacrine; Animals; Anthracenes; Antineoplastic Agents; Blood Physiological Phenomen | 1985 |
Amsacrine (AMSA)--a clinical review.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 1985 |
Clinical correlations with the human tumor cloning assay.
Topics: Aminoacridines; Amsacrine; Anthracenes; Breast Neoplasms; Clinical Trials as Topic; Clone Cells; Cul | 1985 |
4 trials available for amsacrine and Breast Cancer
| Article | Year |
|---|---|
New cytotoxic drugs for breast cancer and their clinical evaluation.
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as | 1980 |
m-AMSA: an exciting new drug in the National Cancer Institute Drug Development Program.
Topics: Acute Disease; Aminoacridines; Amsacrine; Breast Neoplasms; Clinical Trials as Topic; Dose-Response | 1980 |
Amsacrine (AMSA)--a clinical review.
Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc | 1985 |
Clinical correlations with the human tumor cloning assay.
Topics: Aminoacridines; Amsacrine; Anthracenes; Breast Neoplasms; Clinical Trials as Topic; Clone Cells; Cul | 1985 |
30 other studies available for amsacrine and Breast Cancer
| Article | Year |
|---|---|
Antitumor polycyclic acridines. 7. Synthesis and biological properties of DNA affinic tetra- and pentacyclic acridines.
Topics: Acridines; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, | 2000 |
Fluorescein hydrazones: A series of novel non-intercalative topoisomerase IIα catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells.
Topics: Animals; Antigens, Neoplasm; Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, | 2017 |
Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Breast Neoplasms; Cell Proliferation; Cell Survi | 2019 |
In-silico Design, ADMET Screening, MM-GBSA Binding Free Energy of Some Novel Isoxazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer.
Topics: Amsacrine; Antineoplastic Agents; Breast Neoplasms; Computer Simulation; Drug Design; Ethacridine; F | 2019 |
Pyrazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer - An in-silico approach.
Topics: Amsacrine; Breast Neoplasms; Female; Humans; Ligands; Molecular Docking Simulation; Pyrazoles | 2022 |
Quantitative determination of intracellular Asulacrine in MCF-7 breast cancer cells by liquid chromatography-mass spectrometry and its application to cellular pharmacokinetic studies of P188 modified liposomes.
Topics: Amsacrine; Antineoplastic Agents; Breast Neoplasms; Chromatography, Liquid; Female; Humans; Liposome | 2016 |
Modification of polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection delivery.
Topics: Amsacrine; Animals; Antineoplastic Agents; Breast Neoplasms; Injections, Intravenous; Lipids; Male; | 2012 |
Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation.
Topics: Amsacrine; Animals; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug | 2004 |
Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity.
Topics: Alkylating Agents; Amsacrine; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Do | 2005 |
Phase II study of high-dose amsacrine (AMSA) and autologous bone marrow transplantation in patients with refractory metastatic breast cancer.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Bone Marrow Transplantation; Breast N | 1983 |
A phase II evaluation of m-AMSA, 4'-(9-acridinylamino) methanesulfon-m-anisidide, in patients with breast cancer.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Fe | 1981 |
Phase II trial of AMSA in refractory breast cancer.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Breast Neoplasms; Drug Evaluation; Female; Humans; Middle Ag | 1982 |
Phase II study of AMSA in patients with metastatic breast cancer: a Cancer and Leukemia Group B study.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Fe | 1982 |
AMSA and peptichemio in the treatment of advances metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Dr | 1982 |
[Phase I-II studies of a new antineoplastic agent, 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA)].
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Fe | 1982 |
Amsacrine (AMSA).
Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Breast Neoplasms; Dogs; Dose-Response Rel | 1980 |
Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity.
Topics: Adult; Aged; Amsacrine; Breast Neoplasms; DNA Topoisomerases, Type II; DNA, Neoplasm; ErbB Receptors | 1993 |
Selective reversal of vinblastine resistance in multidrug-resistant cell lines by tamoxifen, toremifene and their metabolites.
Topics: Amsacrine; Animals; Breast Neoplasms; Cell Survival; CHO Cells; Cisplatin; Cricetinae; Dose-Response | 1993 |
Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Topics: Amsacrine; Animals; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Cy | 1996 |
Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors.
Topics: Amsacrine; Bleomycin; Breast Neoplasms; Cell Division; Cell Survival; Cyclic AMP-Dependent Protein K | 1995 |
Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells.
Topics: Amsacrine; Anion Transport Proteins; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agent | 2001 |
Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding | 2001 |
Incidence of mutation and deletion in topoisomerase II alpha mRNA of etoposide and mAMSA-resistant cell lines.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms; DNA Mutational Analysis; DNA | 2001 |
Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase.
Topics: Adenocarcinoma; Amsacrine; Animals; Biomarkers, Tumor; Breast Neoplasms; DNA Damage; DNA Topoisomera | 1991 |
A lack of detectable modification of topoisomerase II activity in a series of human tumor cell lines expressing only low levels of etoposide resistance.
Topics: Amsacrine; Breast Neoplasms; Cell Line; Cell Nucleus; DNA Damage; DNA Topoisomerases, Type II; DNA, | 1991 |
Mitogen-induced topoisomerase II synthesis precedes DNA synthesis in human breast cancer cells.
Topics: Amsacrine; Blotting, Western; Breast Neoplasms; Cross-Linking Reagents; DNA; DNA Topoisomerases, Typ | 1989 |
Evaluation of an amsacrine analog in a human tumor cloning system.
Topics: Amsacrine; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Drug Resistance; Humans; Lung | 1989 |
Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
Topics: Amsacrine; Breast Neoplasms; Cell Survival; DNA Damage; DNA Repair; DNA Topoisomerases, Type II; Dox | 1988 |
Pilot study of adriamycin and amsacrine (m-AMSA) in patients with advanced breast cancer.
Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neo | 1988 |
Phase II study of AMSA and doxorubicin to treat metastatic breast cancer.
Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl | 1986 |